The nation of Zimbabwe has turned down a significant US healthcare agreement valued at 367 million US dollars (£272m) over five years due to Washington's demand for sensitive biological samples.
This move became public following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since stated that the US was requesting biological samples for scientific study and profit while was not willing to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more talks to find a deal acceptable to both sides so the nation's critical HIV programme can proceed.
Wider Implications
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court suspended a related health funding agreement after legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government agreements to boost openness and responsibility.
Based on statements, Sixteen nations in Africa have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"In essence, our country would supply the basic resources for medical research with no assurance that the resulting innovations would be accessible to our population should a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting frameworks previously set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This system is intended to ensure that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how future collaboration might be arranged in a manner that honours the independence and dignity of each country."
Medical Community Reaction
A leading public health body expressed it acknowledged the official position, but recommended that negotiations need to persist considering a large portion of the nation's Aids initiatives were funded by international support.
"Where technical issues arise, including those relating to information security or agreement terms, these can frequently be addressed through technical clarification and mutually agreed protections," the group said.
This impasse emphasises the ongoing challenges between receiving vital international aid and safeguarding national sovereignty in an ever more interconnected world.